A vast number of studies suggested that EZH2 is dramatically elevated in a wide spectrum of human malignancies, such as those of the lung 18, breast 19, prostate 20, gastric 21 and hematological malignancies 22, which provides a promising target for anti-cancer drug therapy. This evidence concerns the gene EZH2 and cancer.